An Insilico Study of Stigmasterol Glucoside for Hypolipidemic Activity

Author: Anant Kumar Patel and Nandu Rangnath Kayande

Journal Name:

Download PDF

Abstract

Hyperlipidemia is a well-known indicator of cardiovascular disease risk. Herbal treatment for hyperlipidemia is widely used. Direct trials in animals and people to check the effectiveness of herbal therapies for dyslipidemia, on the other hand, involve ethical difficulties. Insilico research is used to overcome this challenge. One of the key advantages of in silico studies is that they can be used to predict the effects of different drugs and interventions on lipid metabolism, without the need for costly and time-consuming experiments. For example, in silico studies can be used to predict the binding affinity of different drugs to specific lipid targets, as well as their potential side effects and toxicity. In silico studies can be used to identify new drug targets and develop novel therapies for lipid disorders. By analyzing the structure and function of lipid-related proteins and enzymes, researchers can identify potential drug targets and design new drugs that specifically target these molecules. In silico studies have become an essential tool in the field of lipid disorders, providing valuable insights into the molecular mechanisms underlying these disorders and helping to develop new and more effective treatments for these conditions. The purpose of this research is to use molecular docking to assess the efficacy of Stigmasterol glucoside towards dyslipidemia. After examining several scholarly articles, stigmasterol glucoside was chosen as the ligand. The PubChem database was used to acquire a molecular structure file. The Protein Data Bank was used to get the target's crystal structure. All linked components as well as solvent molecules were removed from the protein molecule. The Biovia Discovery software was used to identify active binding sites. The PyRx program was used to conduct a molecular docking study with Stigmasterol glucoside against HMG-CoA reductase. According to a molecular docking research, stigmasterol glucoside binds to the HMG-CoA reductase receptor with a stronger affinity than atorvastatin. It is possible to infer that Stigmasterol glucoside seems to have the ability to function like a hypolipidemic agent.

Keywords

Stigmasteryl 3-beta-D-glucoside, Molecular Docking, Plant Compound, HMG-CoA Reductase, Hypolipidemic Agent, Lipid, Heart Disease

Conclusion

Hyperlipidemia is a serious issue right now. Traditional therapies may have negative side effects. It is generally established that reducing low-density lipoproteins is associated with a decreased death rate from cardiovascular disease. Nonetheless, certain herbs can be beneficial for those who have the aforementioned illnesses. The ability of plants to lower hyperlipidemia is essential for lowering atherosclerosis. As a result, demand for natural lipid-lowering treatments is rising. Herbal medicines' bioactive ingredients could be able to regulate the complex interventions in lipid metabolism. The key conclusions point to good uses for these medications in a range of patient populations. The bioactive components in herbal medications are also often harmless and well-tolerated. Overall, the use of herbal molecules to treat hyperlipidemia offers a potential alternative to statins that may be safer and provide additional health benefits. However, further research is needed to fully understand the mechanisms behind the lipid-lowering effects of these molecules and to determine their optimal use in clinical practice.

References

-

How to cite this article

Anant Kumar Patel and Nandu Rangnath Kayande (2023). An Insilico Study of Stigmasterol Glucoside for Hypolipidemic Activity. Biological Forum – An International Journal, 15(4): 660-667.